Clinical

Dataset Information

A phase 2 study of combination therapy with irinotecan/ S-1 (IRIS) plus panitumumab as second-line chemotherapy for metastatic colorectal cancer


ABSTRACT: Interventions: Irinotecan (100 mg/m2) and panitumumab (6 mg/kg) on days 1 and 15 and S-1 (40–60 mg according to body surface area) twice daily for 2 weeks, repeated every 4 weeks. Primary outcome(s): Completion rate of protocol therapy Study Design: Single arm Non-randomized

DISEASE(S): Colonrectal Cancer

PROVIDER: 2620105 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR